ZAI LAB LIMITED Repayments of Short-term Debt
ZAI LAB LIMITED (ZLAB) reported Repayments of Short-term Debt of $129.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfShortTermDebt · last filed 2026-08-06
- ZAI LAB LIMITED repayments of short-term debt for the quarter ending 2026-06-30 was $24.42M, a 11.43% increase year-over-year.
- ZAI LAB LIMITED repayments of short-term debt for the quarter ending 2026-03-31 was $105.50M, a 73.22% increase year-over-year.
- ZAI LAB LIMITED repayments of short-term debt for the quarter ending 2025-12-31 was $21.95M, a 1097500.00% increase year-over-year.
- ZAI LAB LIMITED repayments of short-term debt for the quarter ending 2025-09-30 was $34.12M, a 12000.35% increase year-over-year.
- ZAI LAB LIMITED repayments of short-term debt for fiscal 2025 was $138.89M, a 48805.99% increase from fiscal 2024.
- ZAI LAB LIMITED repayments of short-term debt for fiscal 2024 was $284.00K.
- ZAI LAB LIMITED repayments of short-term debt for fiscal 2023 was $0.00.
- ZAI LAB LIMITED repayments of short-term debt for fiscal 2022 was $0.00.
| Period end | Repayments of Short-term Debt 3 month | Repayments of Short-term Debt 6 month | Repayments of Short-term Debt 9 month | Repayments of Short-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $129.92M 10-Q · filed 2026-08-06 | $151.87M derived: sum of 3 quarters · filed 2026-08-06 | $185.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $105.50M 10-Q · filed 2026-05-07 | $127.45M derived: sum of 2 quarters · filed 2026-05-07 | $161.57M derived: sum of 3 quarters · filed 2026-05-07 | $183.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $56.08M derived: sum of 2 quarters · filed 2026-02-26 | $77.99M derived: sum of 3 quarters · filed 2026-08-06 | $138.89M 10-K · filed 2026-02-26 |
| 2025-09-30 | $34.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $56.04M derived: sum of 2 quarters · filed 2026-08-06 | $116.94M 10-Q · filed 2025-11-06 | $116.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $82.82M 10-Q · filed 2026-08-06 | $82.82M derived: sum of 3 quarters · filed 2026-08-06 | $83.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $60.90M 10-Q · filed 2026-05-07 | $60.91M derived: sum of 2 quarters · filed 2026-05-07 | $61.19M derived: sum of 3 quarters · filed 2026-05-07 | $61.19M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $284.00K derived: sum of 2 quarters · filed 2026-02-26 | $284.00K derived: sum of 3 quarters · filed 2026-02-26 | $284.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $282.00K derived: sum of 2 quarters · filed 2025-11-06 | $282.00K 10-Q · filed 2025-11-06 | $282.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2020-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $4.40M derived: sum of 2 quarters · filed 2023-03-01 | $5.10M derived: sum of 3 quarters · filed 2023-03-01 | $6.53M 10-K · filed 2023-03-01 |
| 2020-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $2.86M derived: sum of 2 quarters · filed 2021-11-09 | $4.29M 10-Q · filed 2021-11-09 | $6.41M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $2.13M 10-Q · filed 2021-08-09 | $4.25M derived: sum of 3 quarters · filed 2022-03-01 | $5.74M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.43M 10-Q · filed 2021-05-10 | $3.55M derived: sum of 2 quarters · filed 2022-03-01 | $5.04M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $2.12M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $3.61M derived: sum of 2 quarters · filed 2022-03-01 | $4.35M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $1.49M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $2.23M 6-K · filed 2020-01-21 | ||
| 2019-06-30 | $739.00K 6-K · filed 2020-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |